CUPISCO / MX39795Active, not recruiting

CUPISCO

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
First line
Phase
Phase II

What is this trial about?

The CUPISCO study is investigating the use of targeted therapies or cancer immunotherapies versus chemotherapy in patients with cancer of unknown primary origin.

Detailed description

Cancer of unknown primary (CUP) is a rare tumor that is difficult to treat and is usually metastatic from the outset. Currently, chemotherapy is the best available treatment for this condition. In the CUPISCO study, all patients initially receive 3 cycles of chemotherapy. They are then randomly assigned to one of two treatment options. In the standard treatment option, they continue to receive chemotherapy. In the experimental treatment option, they receive a therapy that was discussed by a specialized tumor board based on the results of the tumor analyses. If the disease has progressed after the initial 3 cycles of chemotherapy, the findings are always reviewed for this patient group by the specialized tumor board.

Trial sites

12 trial sites in Germany are listed. Find a site near you.

  • Universitätsklinikum Augsburg

    Stenglinstraße 2, 86156 Augsburg

    Active, not recruiting

  • Charité-Universitätsm. Berlin

    13353 Berlin

    Status unknown

  • Onkologisches Zentrum - Onkologie Dachau

    85221 Dachau

    Status unknown

  • Universitätsklinikum Frankfurt, UCT

    60590 Frankfurt

    Status unknown

  • Nationales Centrum für Tumorerkrankungen Heidelberg

    Im Neuenheimer Feld 280, 69120 Heidelberg

    Active, not recruiting

  • SLK-Kliniken Heilbronn GmbH- Klinikum am Gesundbrunnen Heilbronn

    Am Gesundbrunnen 20-26, 74078 Heilbronn

    Status unknown

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry (NCT03498521) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.